Abstract
Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.
Original language | English (US) |
---|---|
Journal | Seminars in Oncology |
Volume | 32 |
Issue number | SUPPL. 3 |
DOIs | |
State | Published - Apr 2005 |
ASJC Scopus subject areas
- Oncology